NCT00258154View on ClinicalTrials.gov

V260 Study: Concomitant Use of V260 and INFANRIX™ Hexa in Healthy Infants (V260-010)

PHASE3CompletedINTERVENTIONAL
Enrollment

403

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

November 30, 2006

Study Completion Date

November 30, 2006

Conditions
Rotavirus Disease
Interventions
BIOLOGICAL

Rotavirus Vaccine, Live, Oral, Pentavalent

3 doses of rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2

BIOLOGICAL

Comparator: placebo

3 doses of placebo to rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2

BIOLOGICAL

Comparator: Infanrix(tm) Hexa

3 doses of oral Infanrix(tm) Hexa on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00258154 - V260 Study: Concomitant Use of V260 and INFANRIX™ Hexa in Healthy Infants (V260-010) | Biotech Hunter | Biotech Hunter